ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022
Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Frontiers and hotspot evolution in research on Alzheimer's disease and hypertension: a bibliometric analysis from 2004 to 2023.Frontiers in neurology · 2025Pooled it
- Early-life cognitively stimulating activities and late-life cognitive function in the St. Louis Baby Tooth Later Life Health Study.Scientific reports · 2025Article
- Association of memory function with COVID-19 outcomes in adults aged 50 years and older: analysis of three prospective cohorts.Frontiers in public health · 2025Article
- Changes in cerebrovascular reactivity within functional networks in older adults with long-COVID.Frontiers in neurology · 2025Article
- Neurological complications caused by SARS-CoV-2.Clinical microbiology reviews · 2024Review
- Article
- Shared genetics and causal association between plasma levels of SARS-CoV-2 entry receptor ACE2 and Alzheimer's disease.CNS neuroscience & therapeutics · 2024Article
- Review
- Cognitive Aspects of COVID-19.Current neurology and neuroscience reports · 2023Review
- Risk of Adverse Events and Delirium after COVID-19 Vaccination in Patients Living with Dementia.Journal of the American Medical Directors Association · 2023Article
- Links between COVID-19 and Parkinson's disease/Alzheimer's disease: reciprocal impacts, medical care strategies and underlying mechanisms.Translational neurodegeneration · 2023Review
- Article
- Review
- Mortality and survival in nonagenarians during the COVID-19 pandemic: Unstable equilibrium of aging.Frontiers in medicine · 2023Article
- Article
- Positive Effect of Cognitive Training in Older Adults with DifferentDiagnostics (Basel, Switzerland) · 2022Article
- The COVID-19 pandemic and Alzheimer's disease: mutual risks and mechanisms.Translational neurodegeneration · 2022Review
- Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- microRNA, the Innate-Immune System and SARS-CoV-2.Frontiers in cellular and infection microbiology · 2022Article
- COVID-19 Hospitalization Outcomes for Long-Term Care Facility Residents With Dementia: Mediation by Pre-existing Health Conditions.Gerontology & geriatric medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
introductionAlzheimer's disease (AD) and COVID-19 share common risk factors including hypertension. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are frequently prescribed antihypertension medications.
methodsThis study analyzed 436,823 veterans tested for SARS-CoV-2 infection. We conducted both classical and propensity score weighted logistic models to compare COVID-19 outcomes between patients with AD or mild cognitive impairment (MCI) to those without cognitive impairment, and examined effect of ACEI/ARB prescription.
resultsThere was a statistically significant association between AD and increased odds of infection and mortality. MCI was not found to be a risk factor for infection. Subjects with MCI exhibited poor clinical outcomes. Prescribing ARBs but not ACEIs was significantly associated with a lower risk of COVID-19 occurrence among AD and MCI patients. DISCUSSION: Exploring beneficial effects of existing medications to reduce the impact of COVID-19 on patients with AD or MCI is highly significant. HIGHLIGHTS: There is significant association between Alzheimer's disease (AD) and increased risk of COVID-19 infection and odds of mortality. Subjects with mild cognitive impairment (MCI) defined by claims data exhibit poor clinical outcomes, but MCI was not found to be a risk factor for severe acute respiratory syndrome coronavirus 2 infection. Prescribing angiotensin II receptor blockers was significantly associated with a lower risk of COVID-19 occurrence among AD/MCI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.